| The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ... leukemia 36 (7), 1703-1719, 2022 | 2938 | 2022 |
| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ... Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013 | 2664 | 2013 |
| Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma … J BladÉ, D Samson, D Reece, J Apperley, B BJÖrkstrand, G Gahrton, ... British journal of haematology 102 (5), 1115-1123, 1998 | 2012 | 1998 |
| Defining the intensity of conditioning regimens: working definitions A Bacigalupo, K Ballen, D Rizzo, S Giralt, H Lazarus, V Ho, J Apperley, ... Biology of blood and marrow transplantation 15 (12), 1628-1633, 2009 | 1971 | 2009 |
| Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet M Baccarani, J Cortes, F Pane, D Niederwieser, G Saglio, J Apperley, ... Journal of clinical oncology 27 (35), 6041-6051, 2009 | 1897 | 2009 |
| Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet M Baccarani, G Saglio, J Goldman, A Hochhaus, B Simonsson, ... Blood 108 (6), 1809-1820, 2006 | 1853 | 2006 |
| European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia A Hochhaus, M Baccarani, RT Silver, C Schiffer, JF Apperley, F Cervantes, ... Leukemia 34 (4), 966-984, 2020 | 1506 | 2020 |
| A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ... New England Journal of Medicine 369 (19), 1783-1796, 2013 | 1331 | 2013 |
| Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib D Marin, A Bazeos, FX Mahon, L Eliasson, D Milojkovic, M Bua, ... Journal of clinical oncology 28 (14), 2381-2388, 2010 | 1154 | 2010 |
| Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity S Wahl, A Drong, B Lehne, M Loh, WR Scott, S Kunze, PC Tsai, JS Ried, ... Nature 541 (7635), 81-86, 2017 | 956 | 2017 |
| Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation A Gratwohl, J Hermans, JM Goldman, W Arcese, E Carreras, A Devergie, ... The Lancet 352 (9134), 1087-1092, 1998 | 887 | 1998 |
| Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia JF Apperley The lancet oncology 8 (11), 1018-1029, 2007 | 877 | 2007 |
| Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy A Hochhaus, HM Kantarjian, M Baccarani, JH Lipton, JF Apperley, ... Blood 109 (6), 2303-2309, 2007 | 835 | 2007 |
| Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta JF Apperley, M Gardembas, JV Melo, R Russell-Jones, BJ Bain, EJ Baxter, ... New England Journal of Medicine 347 (7), 481-487, 2002 | 781 | 2002 |
| Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis H De Lavallade, JF Apperley, JS Khorashad, D Milojkovic, AG Reid, ... Journal of Clinical Oncology 26 (20), 3358-3363, 2008 | 731 | 2008 |
| Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation A Galleu, Y Riffo-Vasquez, C Trento, C Lomas, L Dolcetti, TS Cheung, ... Science translational medicine 9 (416), eaam7828, 2017 | 644 | 2017 |
| Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With … D Marin, AR Ibrahim, C Lucas, G Gerrard, L Wang, RM Szydlo, RE Clark, ... Journal of Clinical Oncology 30 (3), 232-238, 2012 | 613 | 2012 |
| Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial JE Cortes, DW Kim, J Pinilla-Ibarz, PD le Coutre, R Paquette, C Chuah, ... Blood, The Journal of the American Society of Hematology 132 (4), 393-404, 2018 | 602 | 2018 |
| Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis J Cortes, P Rousselot, DW Kim, E Ritchie, N Hamerschlak, S Coutre, ... Blood 109 (8), 3207-3213, 2007 | 582 | 2007 |
| Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase … F Ciceri, C Bonini, MTL Stanghellini, A Bondanza, C Traversari, ... The lancet oncology 10 (5), 489-500, 2009 | 567 | 2009 |
